These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 28584572)

  • 1. Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology.
    Naoum GE; Buchsbaum DJ; Tawadros F; Farooqi A; Arafat WO
    Oncol Rev; 2017 Mar; 11(1):332. PubMed ID: 28584572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of nanotechnology and gene delivery systems in TRAIL-based therapies.
    Naoum GE; Tawadros F; Farooqi AA; Qureshi MZ; Tabassum S; Buchsbaum DJ; Arafat W
    Ecancermedicalscience; 2016; 10():660. PubMed ID: 27594905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAIL Mediated Signaling in Breast Cancer: Awakening Guardian Angel to Induce Apoptosis and Overcome Drug Resistance.
    Yin N; Yi L; Khalid S; Ozbey U; Sabitaliyevich UY; Farooqi AA
    Adv Exp Med Biol; 2019; 1152():243-252. PubMed ID: 31456187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAIL-based therapeutic approaches for the treatment of pediatric malignancies.
    Gasparini C; Vecchi Brumatti L; Monasta L; Zauli G
    Curr Med Chem; 2013; 20(17):2254-71. PubMed ID: 23458616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR.
    Bremer E; Samplonius DF; van Genne L; Dijkstra MH; Kroesen BJ; de Leij LF; Helfrich W
    J Biol Chem; 2005 Mar; 280(11):10025-33. PubMed ID: 15644326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells.
    El-Mesery M; Trebing J; Schäfer V; Weisenberger D; Siegmund D; Wajant H
    Cell Death Dis; 2013 Nov; 4(11):e916. PubMed ID: 24232092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies.
    Dianat-Moghadam H; Heidarifard M; Mahari A; Shahgolzari M; Keshavarz M; Nouri M; Amoozgar Z
    Pharmacol Res; 2020 May; 155():104716. PubMed ID: 32084560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA regulation of TRAIL mediated signaling in different cancers: Control of micro steering wheels during the journey from bench-top to the bedside.
    Fayyaz S; Javed Z; Attar R; Farooqi AA; Yaylim I; Ahmad A
    Semin Cancer Biol; 2019 Oct; 58():56-64. PubMed ID: 30716480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
    Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
    Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.
    Holoch PA; Griffith TS
    Eur J Pharmacol; 2009 Dec; 625(1-3):63-72. PubMed ID: 19836385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting TRAIL in the treatment of cancer: new developments.
    Lim B; Allen JE; Prabhu VV; Talekar MK; Finnberg NK; El-Deiry WS
    Expert Opin Ther Targets; 2015; 19(9):1171-85. PubMed ID: 26004811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
    Rowinsky EK
    J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies.
    Secchiero P; Vaccarezza M; Gonelli A; Zauli G
    Curr Pharm Des; 2004; 10(29):3673-81. PubMed ID: 15579063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TRAIL to cancer therapy: Hindrances and potential solutions.
    Wong SHM; Kong WY; Fang CM; Loh HS; Chuah LH; Abdullah S; Ngai SC
    Crit Rev Oncol Hematol; 2019 Nov; 143():81-94. PubMed ID: 31561055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
    Wang S
    Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting TRAIL towards the clinic.
    Mahalingam D; Oldenhuis CN; Szegezdi E; Giles FJ; de Vries EG; de Jong S; Nawrocki ST
    Curr Drug Targets; 2011 Dec; 12(14):2079-90. PubMed ID: 21777191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y; Zhang B
    Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.
    Frew AJ; Lindemann RK; Martin BP; Clarke CJ; Sharkey J; Anthony DA; Banks KM; Haynes NM; Gangatirkar P; Stanley K; Bolden JE; Takeda K; Yagita H; Secrist JP; Smyth MJ; Johnstone RW
    Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11317-22. PubMed ID: 18685088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy.
    Kretz AL; von Karstedt S; Hillenbrand A; Henne-Bruns D; Knippschild U; Trauzold A; Lemke J
    Cancers (Basel); 2018 Mar; 10(3):. PubMed ID: 29562636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.